FDA-Approved Indications for PD-L1 Testing

ORDER
PD-L1 22C3 by IHC
PD-L1 scoring and interpretationa
(with TPS or CPS) will be provided
based on tumor type and origin as
determined by an ARUP
pathologist

ORDER
PD-L1 22C3 by IHC
PD-L1 scoring and interpretationa
(with TPS or CPS) will be provided
based on tumor type and origin as
determined by an ARUP
pathologist

ORDER
PD-L1 28-8 pharmDx by IHC with
interpretation, nivolumab
(OPDIVO)

CONSIDER
PD-L1 28-8 pharmDx by IHC with
interpretation, nivolumab
(OPDIVO)

Abbreviations
CPS       Combined positive score
ESCC      Esophageal squamous cell carcinoma
GEJ       Gastroesophageal junction
HNSCC     Head and neck squamous cell carcinoma
IHC       Immunohistochemistry
NSCLC     Non-small cell lung cancer
PD-L1      Programmed death-ligand 1
TNBC      Triple-negative breast cancer
TPS       Tumor proportion score

aPD-L1 expression interpretation: Please refer to the full prescribing information for tumor-specific indications and expression level cutoff.

© 2023 ARUP Laboratories. All Rights Reserved. www.arupconsult.com Content reviewed: May 2024 Last update: May 2024